Compare Quest Diagnostics Inc (DGX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs DENTSPLY SIRONA Inc — how do they compare? Quest Diagnostics Inc trades at $205.66 (market cap $22.80B), while DENTSPLY SIRONA Inc trades at $13.27 (market cap $2.55B). The key difference: Quest Diagnostics Inc is far larger — about 8.9× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| DGX | XRAY | |
|---|---|---|
Market Cap | $22.80B | $2.55B |
Sector | Health | Health |
52-Week High | $216.02 | $16.85 |
52-Week Low | $166.42 | $9.64 |
Enterprise Value | $28.82B | $4.69B |
Dividend Yield | 1.67% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Dentsply Sirona (XRAY) trades at $12.78, up 4.24% today, with technical indicators showing bullish momentum despite recent earnings misses. The company faces fundamental challenges with negative net income margins (-17.06%) and declining revenue trends, though it maintains a solid gross margin of 48.93%. Recent developments include new CFO appointment and expanded distribution partnerships, while analyst consensus remains mixed with a $13.33 price target.
The stock presents a turnaround opportunity with improving cash flow trends and strategic initiatives, but faces significant execution risks amid persistent profitability challenges. Near-term catalysts include Q2 2026 earnings and continued progress on the Return-to-Growth plan, though high debt levels and competitive pressures warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
